A newly introduced New Jersey bill would require licensed marijuana retailers to conspicuously display warnings at the point of sale about potential health risks associated with high-potency products.
Assembly Bill 5463, introduced September 14 by Assemblywoman Aura Dunn (R), would require the New Jersey Cannabis Regulatory Commission to develop the notice and determine what qualifies as “high potency” marijuana. The measure has been referred to the Assembly Oversight, Reform and Federal Relations Committee.
Under the bill, the warning would be required to include information about potential health risks associated with consuming high-potency marijuana, including risks for people under 25 and for individuals who have, or are at risk of developing, a mental health condition or psychotic disorder.
The notice would also be required to provide information about where consumers can find assistance and resources for reducing or stopping marijuana use.
Unlike proposals that establish THC limits, the bill itself would not set a numerical potency threshold. Instead, the Cannabis Regulatory Commission would be responsible for defining what constitutes high-potency marijuana for purposes of the warning requirement. The legislation also would not prohibit the sale of products that meet that definition.
Retailers would be required to display the commission-developed notice “conspicuously” at the point of sale. The measure does not establish a separate warning requirement for individual product packaging.
The legislation would take effect on the first day of the ninth month following enactment, giving regulators and retailers time to prepare for the new requirement. The commission would be authorized to begin administrative work before the effective date.
The bill’s legislative statement says the proposal is modeled on legislation enacted in Washington state in 2024.
Washington law requires marijuana retailers to post a conspicuous point-of-sale notice addressing potential health risks associated with high-THC marijuana, heightened risks for people under 25 and people with or at risk for certain mental health conditions or psychotic disorders, and resources for people seeking to reduce or stop marijuana consumption. Washington retailers have been required to display the notice since December 31, 2024.
The New Jersey proposal comes amid increased attention to marijuana potency and laboratory testing in the state.
A 2026 report from the New Jersey Office of the State Auditor found that the average reported THCA potency of marijuana flower increased from 24.5% in 2023 to 27.81% in 2025 through September 30, an increase of 13.48%.
The three laboratories that handled nearly 95% of the testing market in 2025 recorded an average increase in reported potency of 20.77% over the period reviewed, with one laboratory showing an increase of 33.25%.
However, the auditor also raised questions about the reliability of laboratory results, finding that the Cannabis Regulatory Commission lacked tools and procedures to effectively monitor reported testing data and did not have an independent system for testing randomized samples to verify laboratory results. The auditor said those oversight deficiencies led to “questionable test results” and potential health and safety risks.
New Jersey voters approved recreational marijuana legalization through a constitutional amendment in 2020, with licensed adult-use sales beginning in April 2022. The market is regulated by the New Jersey Cannabis Regulatory Commission.
Assembly Bill 5463 must advance through committee before it can be considered by the full Assembly. No hearing or vote has been scheduled.
